Management Team

Riikka Havunen

PhD, Head of R&D

Head of R&D, Riikka Havunen, is a highly skilled expert in oncolytic viruses and cancer immunotherapy. Riikka has a PhD from the Cancer Gene Therapy Group (Helsinki, Finland). Riikka had a key role in development of TILT-123, which was the focus of her PhD. Riikka heads Quality and CMC activities and translating the preclinical research into clinical development.

Akseli Hemminki

MD, PhD, eMBA, Founder & CEO and Chairman of the Board

Aino Kalervo

MSc, MS, Chief Business Officer

Kari Varkila

MD, PhD, MBA, Chief Medical Officer

Elina Haavisto

MSc, Head of CMC Regulatory Affairs

Claudia Kistler

PhD, Head of Clinical Operations

no image

Suvi Sorsa

PhD, Head of Clinical Research

Víctor Cervera-Carrascón

M.Pharm, Head of Immunology

Riikka Kalliokoski

Bachelor of Social and Health Care, Lab manager

João Manuel Santos

MSc, Head of Cell Therapy

Remi Gloeckler

PhD, CMC Advisor

Tuija Keinonen

PhD, Chief Regulatory Officer